Correction to: Impacts of the regulatory environment for gene editing on delivering beneficial products

Daniel Jenkins1 · Raymond Dobert2 · Ana Atanassova3 · Chloe Pavely4

Published online: 10 January 2022
© The Society for In Vitro Biology 2022

Correction to: In Vitro Cell Dev Biol-Plant
https://doi.org/10.1007/s11627-021-10201-4

The reference to Van der Meer et al. 2020 in this article was misattributed and should have been removed from the final version in the text on page 615 and in the References. This sentence should appear as follows:

The ECJ ruling placed products developed using “new” techniques like genome editing within the scope of the GMO directive (Vives-Vallés and Collonnier 2020).

The original article can be found online at https://doi.org/10.1007/s11627-021-10201-4.

Daniel Jenkins
djenkins@pairwise.com

1 Pairwise Plants Services, Inc., 807 East Main Street, Suite 4-100, Durham, NC 27701, USA
2 Bayer Crop Science, 700 Chesterfield Parkway West, St. Louis, MO 63017, USA
3 BASF Business Coordination Centre – Innovation Center Gent, Technologiepark 101, 9052 Gent, Belgium
4 Calyxt, Inc., 2800 Mount Ridge Road, Roseville, MN 55113, USA

Springer